ABSTRACT OF THE DISCLOSURE

This invention provides compounds of formula I,

$$R_2$$
 R_3
 R_4
 R_4
 R_1
 R_4
 R_1

5 I

wherein

R is hydrogen or alkyl of 1-6 carbon atoms;

R' is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, alkyl of 1-6 carbon atoms,

alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, or trifluoroalkoxy of 1-6 carbon atoms;

X is CR₅R₆ or a carbonyl group;

R₅ and R₆ are each, independently, hydrogen or alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof, with the proviso that at least two of R₁,

15 R_2 , R_3 , or R_4 are not hydrogen;

which are 5HT_{2C} receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.

20